-
About Createrna
An Innovative Company Driven by R&D Pipeline and Platform
Createrna is an innovative drug research and development company in the clinical stage. Adhering to the dual-driven strategy of simultaneous development of the R&D pipeline and platform, the company has built a new drug research and development system covering the whole process from proof-of-concept, candidate compound screening, preclinical druggability development to clinical research.
-
240+
Employee
-
180+
Researchers
-
15+
Projects
-
25+
Pipelines
-
200+
Patents
-
300+
Partners
The Global Distribution
-
Wuhan R&D Center
Wuhan, China Wuhan High-tech Zone National biological Industry Base
The integrated center for functional operations management and preclinical research and development. There are project management department, pharmaceutical department, Pharmacology Department and intellectual Property Department, which provide research and development services include POC, in vitro and in vivo model construction and drug synthesis for clinical projects.
-
Translational Medicine Center
Wuhan, China Wuhan High-tech Zone National biological Industry Base
Responsible for exploring clinical needs by integrating external expert resources, determining the relationship between targets and disease development, exploring and verifying the mechanism of action of drugs, discovering and selecting biomarkers, exploring product differentiation advantages, participating in the evaluation of clinical research strategies, and helping to improve the efficiency and success rate of new drug research and development.
-
Clinical Medical Center
New Changjiang Plaza, 2 Youyi Avenue, Wuchang District, Wuhan City, China
Led the company's clinical trials of innovative drugs, and was responsible for the clinical safety and efficacy studies, clinical pharmacology studies, compliance management of trial execution, clinical transfer and CRO, and construction of clinical base resources from before and after IND to market.
-
Shanghai R&D Center
Building A, 3333 Shenjiang Road, Pudong New Area, Shanghai, China
The R&D branch center consists of project management department, pharmacy department, Pharmacology Department and Intellectual Property Department, which is responsible for providing R&D services such as proof of concept, in vitro and in vivo model construction and drug synthesis for clinical projects.
-
International Center
Maryland, USA
Business development and FDA application for customers and investors of pharmaceutical companies in the United States and Europe, connecting research centers of the company with foreign pharmaceutical companies and scientific research institutions.
Development Course
-
In May 2013
Createrna Development Co., Ltd. was established
-
In March 2015
Early activity screening evaluation model construction team was established;
In vivo model building platform is completed
-
In August 2018
A medical information platform has been established;
Obtained the national intellectual Property Management system certification
-
In September 2021
Awarded as excellent high-tech enterprise;
PHN treatment MY008211A tablet entered Phase I clinical trials;
The IBD treatment MY009212A tablet entered Phase I clinical trials;
Dr. Yaning Wang has been appointed CEO of Createrna
-
In October 2021
Chronic cough treatment QR052107B tablets entered Phase I clinical trials;
Rheumatoid arthritis treatment MY004567 entered Phase I clinical trials
-
In March 2022
P2X3 receptor antagonist enters Phase II clinical trials;
Chronic pain treatment QR0606127 capsules entered Phase I clinical trials;
A clinical medical center has been established
-
In April 2022
Dr. Jing Zhang has been appointed CMO of Createrna
-
In April 2023
A research center for translational medicine has been established
Management Team
-
CEO
Yaning Wang
Twenty years of drug development and regulatory experience
Former Director, Division of Pharmacometrics, Office of Clinical Pharmacology, U.S. FDA
Ph.D. in pharmaceutics and M.S. in statistics from University of Florida, M.S. in biochemistry from national doping control center of China, B.S. in pharmacy from Peking University
Regulatory expert for three new drug development and regulatory training courses: American Course on Drug Development and Regulatory Sciences, European Course in Pharmaceutical Medicine, Chinese Course on Drug Development and Regulatory Sciences
Former Board Director of International Society of Pharmacometrics (ISoP) and current ISoP fellow
Member of the Advisory Committee for Chinese Pharmacometrics Society
Adjunct Professor in University of Florida, Peking University, and Shanghai University of Traditional Chinese Medicine
Over 120 papers published in prestigious journals
Over 380 presentations at various national and international meetings as an expert in new drug development and regulation
Top Healthcare Technology Leaders of Washington, DC for 2023
-
CMO
Jing Zhang
Doctor of Physiology, National Defense Medical University;
Former Clinical Team Leader, Center for Drug Review and Research, U.S. FDA;
Former director of clinical research and development at Janssen Pharmaceuticals;
Former executive director of clinical research and development at Allergan;
Former Executive Director of clinical Research and development at AbbVie;
Former CMO of pharmaceuticals at Axter Therapeutics.
-
CFO
Heng Wang
EMBA of Tsinghua University, EMPACC of Chinese University of Hong Kong, Bachelor of Shanghai University of Finance and Economics
Executive Director of Investment Banking Department, Sponsor, Ping An securities Co., Limited.
Investment Director of Shanghai Pudong Technology Investment Company
Managing Director of Investment Banking Department, Sponsor, Shengang Securities Co., Ltd.
-
Vice President of Clinical Medicine Center
Wei Feng
Doctor of Medicine, Huazhong University of Science and Technology;
Evaluation expert of Science and Technology Expert Database of Hubei Provincial Department of Science and Technology
-
Senior Vice President
Yihan Zhang
Master of Pharmacy, Hubei Universityp;
General Manager of Wuhan R&D Center.
-
Vice President of Translational Medicine Center
Li Liu
Master of Pharmacokinetics, Hubei University;
Chinese Society of Toxicology Toxicologist;
Former project leader of the drug evaluation Department of AppTec.
-
Vice President of Wuhan R&D Center
Jun Lou
Doctor of Pharmaceutical Chemistry, Wuhan University;
Postdoctoral Fellow of Pharmacy, Huazhong University of Science and Technology;
National licensed pharmacist.
-
Vice President of Shanghai R&D Center
Linbo Luan
Doctor of Organic Chemistry from Fudan University, Master of Pharmaceutical Engineering from Tianjin University;
Former scientist at GlaxoSmithKline (Shanghai) Pharmaceutical R&D Co., LTD.
Honors and Qualifications
-
National High-Tech Enterprise
-
National Torch Plan Key High-Tech Enterprise
-
National Postdoctoral Research Station
-
National and Local Joint Engineering Research Center
